Human medicines European public assessment report (EPAR): Bavencio, avelumab, Date of authorisation: 18/09/2017, Revision: 23, Status: Authorised

Scientific advice and protocol assistance adopted during the CHMP meeting 20-23 April 2026

Human medicines European public assessment report (EPAR): Exjade, deferasirox, Date of authorisation: 28/08/2006, Revision: 58, Status: Authorised

Human medicines European public assessment report (EPAR): Ceprotin, human protein C, Date of authorisation: 16/07/2001, Revision: 21, Status: Authorised

List of eligible industry stakeholder organisations

Human medicines European public assessment report (EPAR): Kisqali, ribociclib, Date of authorisation: 22/08/2017, Revision: 26, Status: Authorised

EMA closed on Whit Monday, 25 May

Guidance on the details of the classification of variations requiring assessment according to Article 62 of Regulation (EU) 2019/6 for veterinary medicinal products and on the documentation to be submitted pursuant to those variations

Virtual live hands-on training course for clinical trials sponsors using EudraVigilance system - November 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, from 24 November 2026, 14:00 (CET) to 26 November 2026, 18:00 (CET)

Virtual live hands-on training course for clinical trials sponsors using EudraVigilance system - October 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, from 6 October 2026, 09:00 (CEST) to 8 October 2026, 13:00 (CEST)